Articles related to PROSTATE CANCER

A randomized noninferiority trial involving 648 men with MRI-visible prostate lesions found that cognitive fusion biopsy achieved clinically significant prostate cancer detection rates similar to software-based fusion biopsy. Subgroup analyses suggested body mass index may influence the relative performance of each approach.

A two-year analysis of 12,670 screened men found that the Stockholm3 risk model detected more clinically significant prostate cancers than PSA testing alone, primarily through fewer false-negative results. The findings suggest improved screening discrimination, although follow-up remains limited to two years.

A repeat PSMA PET/CT scan detected recurrent disease in more than half of prostate cancer patients whose initial scan was negative. Findings altered management in nearly half of patients, particularly those with oligometastatic recurrence.

A multivariable screening test detects 90% of clinically significant prostate cancers vs 74% with PSA alone, suggesting PSA thresholds may miss aggressive disease despite similar false-positive rates.

In a retrospective VA cohort of 669 mCRPC patients who did not progress on initial docetaxel, rechallenge with docetaxel was associated with improved overall survival compared with cabazitaxel after inverse probability of treatment weighting, though short follow-up and inherent selection pressures limit interpretation.

Perioperative apalutamide plus ADT, six months before and after radical prostatectomy, achieved a ninefold improvement in major pathologic response and a 20% reduction in metastasis-free survival events versus placebo plus ADT in patients with high-risk localized or locally advanced prostate cancer in a phase 3 trial.